New Global Initiative by Boehringer Ingelheim and WHO Foundation to Tackle Obesity and Metabolic Health

Addressing Obesity: A New Front in Global Health

In a significant new partnership, Boehringer Ingelheim has joined forces with the WHO Foundation to combat one of the most pressing health challenges of our time: obesity and its associated metabolic conditions. This collaboration, announced on September 24, 2026, will span three years and is backed by a generous contribution of $5 million from Boehringer Ingelheim, aimed at improving healthcare systems and patient outcomes worldwide.

Understanding the Obesity Crisis

Obesity is not just a personal health issue; it represents a global epidemic affecting billions. Recent statistics highlight that over 2.5 billion adults and 390 million children are classified as overweight, with alarming rates of obesity doubling among adults since 1990. The consequences of this condition extend beyond individual health; they pose a significant burden on healthcare systems and associated sectors, affecting cardiovascular health, kidney and liver function, and overall metabolic well-being.

Goals of the Collaboration

The partnership aims to fortify the preparedness of health systems, particularly in resource-limited settings, to monitor and manage obesity and related metabolic health issues. One of its critical objectives is to foster a new approach that integrates health and non-health sectors, thereby considering the voices of individuals living with non-communicable diseases (NCDs) in policy development. This inclusive approach is anticipated to ensure that care provided is patient-centered and impactful.

Anil Soni, CEO of the WHO Foundation, emphasized the necessity of a coordinated strategy to tackle these interconnected diseases. He stated, "The scale and complexity of the obesity and metabolic health challenge calls for an integrated approach that will strengthen the foundations of care. Through this collaboration with Boehringer Ingelheim, we will enable countries to translate evidence and global guidance into integrated services that respond to people's needs."

Implementation of the Acceleration Plan

As part of this initiative, the WHO Foundation will also support the implementation of the WHO's Acceleration Plan to Stop Obesity (2022–2030). This foundational plan encourages countries to move from awareness to actionable strategies, utilizing evidence-based interventions and fostering systemic change.

Boehringer Ingelheim's Shashank Deshpande remarked on the necessity of recognizing the shared drivers between obesity and its related conditions. He stated, "Obesity and related metabolic diseases cannot be addressed effectively in isolation. They require health systems that recognize their shared drivers and provide coordinated, long-term care."

Through this collaboration, Boehringer Ingelheim and the WHO Foundation aim to transform global ambitions into effective and sustainable healthcare solutions. By linking obesity management with broader public health initiatives, they hope to create a more robust framework for comprehensive care that addresses chronic conditions fundamentally.

Conclusion

The joint effort embodies a critical step in rethinking how healthcare systems can better support individuals facing these interconnected health challenges. By establishing a model that effectively connects various health areas and emphasizes collaborative care, this initiative holds the potential to redefine how societies respond to obesity and metabolic health. Long-term sustainability and inclusivity remain at the forefront of this groundbreaking partnership, marking a hopeful chapter in global health initiatives aimed at improving the quality of life for millions.

For more information about Boehringer Ingelheim’s engagement in public health and collaborative initiatives, visit boehringer-ingelheim.com.